A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working. "All other studies of amcenestrant, including in early-stage breast cancer (AMEERA-6), will be discontinued," Sanofi said.